Coherus Oncology, Inc. (CHRS) vs Satellos Bioscience Inc. (MSLE)

Coherus Oncology, Inc. and Satellos Bioscience Inc. are both Biotechnology companies. Coherus Oncology, Inc. and Satellos Bioscience Inc. are of similar size ($184.8M and $183.9M). Satellos Bioscience Inc. has the higher net margin (0.00% vs −259.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Satellos Bioscience Inc. leads on 8 and Coherus Oncology, Inc. on 5.

Valuation

Metric CHRS MSLE Biotechnology median
P/E n/m n/m 7.88
P/S 3.43 n/m 11.47
P/B 2.88 3.03 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 5.53 n/m 10.73
Earnings yield (91.15%) (22.07%) (28.84%)
Free cash flow yield (106.88%) (16.01%) (23.03%)

Profitability

Metric CHRS MSLE Biotechnology median
Gross margin 68.94% — 65.16%
Operating margin (311.56%) 0.00% 0.00%
Net margin (259.41%) 0.00% 0.00%
Free cash flow margin (365.22%) 0.00% 0.00%
Return on equity (146.27%) (70.45%) (57.72%)
Return on assets (41.90%) (64.76%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CHRS MSLE Biotechnology median
Revenue growth (TTM) 61.00% — 5.64%
EPS growth (last fiscal year) 472.00% 21.20% —
Revenue growth, 5-year CAGR (38.41%) — 8.40%
Net income growth, 5-year CAGR 4.91% 0.00% 0.00%

Health

Metric CHRS MSLE Biotechnology median
Debt to equity 0.61 0.00 0.00
Current ratio 1.77 11.22 4.73
Net debt to EBITDA 0.76 1.05 0.96

Dividend

Metric CHRS MSLE Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric CHRS MSLE Biotechnology median
Market cap 183.86m 184.83m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack